Latest Breaking News On - Dsenthil damodaran - Page 1 : comparemela.com

Sermonix to Host KOL Fireside Chat on Advancements in the Metastatic Breast Cancer Treatment Landscape on April 22, 2024

COLUMBUS, Ohio, April 19, 2024 (GLOBE NEWSWIRE) Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC)

Dana farber cancer instituteUnited statesDsenthil damodaranSimon jenkinsPaul plourdeElizabeth attiasDavid portmanBarry kommMiriam portmanHarvard medical schoolParke davis pharmaceuticalsUniversity of miamiSermonix pharmaceuticals incPhd md anderson cancer centerHospital cancer centerPhd harvard medical school

Combination Shows Promise in Metastatic ESR1-Mutant Breast Cancer

Durable responses with lasofoxifene plus abemaciclib in post-CDK4/6 inhibitor setting

United statesMayo clinic in rochesterMatthew goetzDsenthil damodaranCharles bankheadUniversity of texas md anderson cancer centerHarvard medical schoolCancer centerMayo clinicSeth wanderMassachusetts general hospitalMedpage today

ESR1 Coalteration Treatment Resistance Does Not Impact Lasofoxifene/Abemaciclib Efficacy in ESR1+ Metastatic Breast Cancer

The presence of ESR1 coabnormalities, including TP53 and PIK3CA mutations, and CCND1 and FGFR1 amplification, did not demonstrate a negative impact on the efficacy with lasofoxifene and abemaciclib in patients with estrogen receptor–positive, ESR1-mutant metastatic breast cancer.

San antonioUnited statesDsenthil damodaranUniversity of texas md anderson cancer centerAntonio breast cancer symposiumCancer centerMetastatic breast cancerBreast cancerSan antonio breast cancer symposiumPhase 2 elaine studyEsr1 coalterationTp53 and pik3caEstrogen receptor positive

Dr Damodaran on Futibatinib Plus Fulvestrant in FGFR1-Amplified HR+/HER2– Breast Cancer

Senthil Damodaran, MD, PhD, discusses the efficacy of futibatinib plus fulvestrant in patients with FGFR1-amplified metastatic hormone receptor–positive, HER2-negative breast cancer according to findings from the phase 2 FOENIX-MBC2 trial.

United statesSan antonioDsenthil damodaranDepartment of breast medical oncologyUniversity of texas md anderson cancer centerDivision of cancer medicineBreast medical oncologyCancer medicineCancer centerAntonio breast cancerPatients with estrogen receptor positiveEr2 negative metastatic breast cancer harboring esr1 mutationsThe university of texas md anderson cancer centerFgfr1 amplificationFoenix mbc2

SABCS: New Targeted Treatments Show Promise for Metastatic HR+/HER2- Breast Cancer

SABCS: New Targeted Treatments Show Promise for Metastatic HR+/HER2- Breast Cancer
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United statesSarina piha paulDsenthil damodaranTransthera bioTransthera sciences nanjing incTaiho oncology incUniversity of texas md anderson cancer centerNational cancer instituteCancer centerAntonio breast cancer symposiumBreast medical oncologyInvestigational cancer therapeuticsTaiho oncologyTransthera sciences